Clinical Trial Update: Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial results show that Fingolimod (FTY720) demonstrated efficacy and acceptable safety in relapsing-remitting multiple sclerosis, with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Gilenya (Fingolimod) (Fingolimod)

Snippet

Sponsor: Novartis | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2012-06-26